Search PubMed⌕ Search

Biomedical subjects

R D Rubens

Publications and source records attributed to R D Rubens.

At least 199 records · Page 11Linked to original sources
PubMed1980

Oestrogen receptors and response to cytotoxic chemotherapy in advanced breast cancer.

Of 54 patients with advanced breast cancer, 21/37 (57%) with oestrogen receptor-positive (ER+) tumours and 11/17 (65%) with oestrogen receptor-negative (ER-) tumours responded to cytotoxic chemotherapy. These data and a survey of the literature indicate that oestrogen receptor status is not a determinant of response to chemotherapy. However, ER+ tumours seem to grow more slowly than ER- ones and the response to chemotherapy tends to be longer in ER+ patients.

Antineoplastic Agents↗
PubMed1979

Elastosis and response to endocrine therapy in human breast cancer.

Response to endocrine therapy in 51 patients with advanced breast cancer was compared with the amount of elastosis in histological sections from their primary tumours. There appeared to be an association between elastosis and response: tumours with no elastosis showed a lower rate of response than those with gross elastosis, indicating that this simple method might provide a useful predictive index for response to endocrine therapy. In addition, tumours with oestrogen-receptor activity (a feature associated with a high rate of response) but with no elastosis were unlikely to respond, suggesting that a combination of the 2 predictive indices might be more valuable than either taken alone.

Breast Neoplasms↗
PubMed1978

Combined cytotoxic and progestogen therapy for advanced breast cancer.

Sixty-nine patients with advanced breast cancer treated with cytotoxic chemotherapy were randomized to receive concomitantly either norethisterone acetate (progestogen group) or a placebo (placebo group). Objective responses were seen in 53% of patients in the progestogen group and 61% of patients in the placebo group. The median duration of response was the same for both groups (38 weeks). Three out of ten patients in the placebo group, who received subsequently the progestogen on relapse, had a further objective regression. The overall survival in the two groups was similar, although in a sub-group of patients who had operable tumors, but a subsequent short disease-free interval, survival was significantly better in the placebo group. There was less myelosuppression in the progestogen group, who were able to receive higher doses of cytotoxic drugs. Less nausea and vomiting occurred in the progestogen group, but subjective side effects were similar. It is concluded that there is no advantage therapeutically in combining cytotoxic chemotherapy and progestogen therapy and, in some patients, better results are obtained using the two treatments sequentially.

Adult↗
PubMed1978

Oestrogen receptors and the response to endocrine therapy in advanced breast cancer.

The relationship between oestrogen-receptor protein (ER) content of the tumour and the response to endocrine therapy was determined in 119 patients, in a collaborative prospective study. Twenty-eight of the 80 patients with measurable ER responded to treatment according to UICC criteria, compared with only 3/39 without ER. It was found that site of biopsy did not influence the result, but tumour content of the tissue sample was significantly related to the presence of receptors. The organizational problems of such a study are discussed.

Breast Neoplasms↗